The National Health Surveillance Agency (Anvisa) authorized, between January and June 2026, a total of 116,372 imports of medicinal cannabis-based products, an increase of almost 29% compared to the same period last year.
Cannabis import authorizations increase 29% in 2026
The National Health Surveillance Agency (Anvisa) authorized, between January and June 2026, a total of 116,372 imports of medicinal cannabis-based products, an increase of almost 29% compared to the same period last year. The numbers are...
According to the report, the month of June registered 18,255 requests, maintaining the increase observed throughout the year. Except for the atypical peak registered in March, with 23,199 authorizations, the average for 2026 has remained at around 20 thousand monthly authorizations, compared to the 15 thousand observed in the first half of 2025.
- In Cannect's assessment, the numbers demonstrate a structural change in patient behavior, indicating that cannabis is no longer an exceptional alternative therapy but has become a...
- LegislationIn February, Anvisa published Collegiate Board Resolution (RDC) 1,015/2026, which updated the regulatory framework on health authorization for the manufacture and import of...
Editorial reading aid based only on information contained in this story and its identified source.
The numbers are part of a survey carried out by Cannect, a health ecosystem focused on comprehensive care for patients with chronic diseases, based on information obtained via the Access to Information Law (LAI).
According to the report, the month of June registered 18,255 requests, maintaining the increase observed throughout the year. Except for the atypical peak registered in March, with 23,199 authorizations, the average for 2026 has remained at around 20 thousand monthly authorizations, compared to the 15 thousand observed in the first half of 2025.
In Cannect's assessment, the numbers demonstrate a structural change in patient behavior, indicating that cannabis is no longer an exceptional alternative therapy but has become a maintenance treatment for thousands of Brazilians with chronic illnesses.
LegislationIn February, Anvisa published Collegiate Board Resolution (RDC) 1,015/2026, which updated the regulatory framework on health authorization for the manufacture and import of cannabis products for human medicinal use, established by RDC 327/2019.
The new standard came into force on May 4 this year, and the agency clarified some of its provisions through questions and answers adapted from questions received through the service channels and technical discussions held during the regulatory review process.
Brazil sees spike in seizures of 'gourmet marijuana' produced in the USA
Marijuana seizures from the United States and Canada exceeded 1 ton in the first seven months of 2026. According to the Federal Police, the increase is linked to the higher concentration of THC, the high commercial value and the ease of transportation in smaller loads